Forty Seven Inc (NASDAQ:FTSV) Director Ravindra Majeti Sells 25,000 Shares

Share on StockTwits

Forty Seven Inc (NASDAQ:FTSV) Director Ravindra Majeti sold 25,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $36.35, for a total value of $908,750.00. Following the completion of the sale, the director now owns 1,087,411 shares of the company’s stock, valued at $39,527,389.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ravindra Majeti also recently made the following trade(s):

  • On Monday, December 16th, Ravindra Majeti sold 25,000 shares of Forty Seven stock. The stock was sold at an average price of $35.49, for a total value of $887,250.00.
  • On Wednesday, November 20th, Ravindra Majeti sold 5,000 shares of Forty Seven stock. The stock was sold at an average price of $12.50, for a total value of $62,500.00.
  • On Monday, November 18th, Ravindra Majeti sold 15,000 shares of Forty Seven stock. The stock was sold at an average price of $10.26, for a total value of $153,900.00.

FTSV stock opened at $45.74 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.48 and a quick ratio of 7.48. The stock has a market capitalization of $1.74 billion, a P/E ratio of -18.90 and a beta of 3.53. The business has a 50-day moving average of $33.65 and a 200-day moving average of $14.49. Forty Seven Inc has a fifty-two week low of $5.53 and a fifty-two week high of $49.50.

Forty Seven (NASDAQ:FTSV) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to analyst estimates of $15.80 million. Equities analysts expect that Forty Seven Inc will post -2.51 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. River & Mercantile Asset Management LLP acquired a new position in shares of Forty Seven during the second quarter worth about $35,000. Tower Research Capital LLC TRC boosted its position in shares of Forty Seven by 5,976.5% during the third quarter. Tower Research Capital LLC TRC now owns 4,132 shares of the company’s stock worth $27,000 after buying an additional 4,064 shares during the period. Metropolitan Life Insurance Co NY acquired a new position in shares of Forty Seven during the first quarter worth about $88,000. Vanguard Group Inc. boosted its position in shares of Forty Seven by 1.2% during the second quarter. Vanguard Group Inc. now owns 499,451 shares of the company’s stock worth $5,294,000 after buying an additional 5,741 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Forty Seven by 18.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 37,899 shares of the company’s stock worth $402,000 after buying an additional 5,867 shares during the period. 54.31% of the stock is owned by institutional investors.

Several equities research analysts have issued reports on the company. Morgan Stanley increased their price target on Forty Seven from $17.00 to $45.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Roth Capital increased their price target on Forty Seven from to and gave the stock a “buy” rating in a report on Tuesday, January 7th. BTIG Research restated a “buy” rating and issued a $40.00 price target on shares of Forty Seven in a report on Tuesday, December 10th. ValuEngine downgraded Forty Seven from a “hold” rating to a “sell” rating in a report on Tuesday, December 10th. Finally, Zacks Investment Research upgraded Forty Seven from a “sell” rating to a “hold” rating in a report on Wednesday, December 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. Forty Seven currently has a consensus rating of “Buy” and an average target price of $36.92.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

See Also: Market Indexes

Insider Buying and Selling by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Fiera Capital Corp Invests $1.09 Million in Pinterest
Fiera Capital Corp Invests $1.09 Million in Pinterest
Fiera Capital Corp Sells 468,443 Shares of iShares MSCI Saudi Arabia Capped ETF
Fiera Capital Corp Sells 468,443 Shares of iShares MSCI Saudi Arabia Capped ETF
Yamana Gold Inc.  Senior Officer Richard Campbell Sells 13,050 Shares
Yamana Gold Inc. Senior Officer Richard Campbell Sells 13,050 Shares
Fiera Capital Corp Reduces Holdings in Activision Blizzard, Inc.
Fiera Capital Corp Reduces Holdings in Activision Blizzard, Inc.
Fiera Capital Corp Sells 7,525 Shares of Lincoln Electric Holdings, Inc.
Fiera Capital Corp Sells 7,525 Shares of Lincoln Electric Holdings, Inc.
Vanguard S&P Small-Cap 600 ETF  Stock Holdings Lowered by Fiera Capital Corp
Vanguard S&P Small-Cap 600 ETF Stock Holdings Lowered by Fiera Capital Corp


© 2006-2020 Ticker Report